International Journal of Hematology

DOI: 10.1007/s12185-019-02778-9 Pages: 182-191

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions

1. Medical University of Vienna, Department of Laboratory Medicine

2. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences

Correspondence to:
Robert Kralovics



Myeloproliferative neoplasms (MPNs) are hematological diseases that are driven by somatic mutations in hematopoietic stem and progenitor cells. These mutations include JAK2, CALR and MPL mutations as the main disease drivers, mutations driving clonal expansion, and mutations that contribute to progression of chronic MPNs to myelodysplasia and acute leukemia. JAK–STAT pathway has played a central role in the disease pathogenesis of MPNs. Mutant JAK2, CALR or MPL constitutively activates JAK–STAT pathway independent of the cytokine regulation. Symptomatic management is the primary goal of MPN therapy in ET and low-risk PV patients. JAK2 inhibitors and interferon-α are the established therapies in MF and high-risk PV patients.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge